Erratum: The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [Ann Oncol, 28, 9, (2017) (2256-2263)] DOI: 10.1093/annonc/mdx305

P. N. Aguiar, L. A. Perry, J. Penny-Dimri, H. Babiker, H. Tadokoro, R. A. de Mello, G. L. Lopes

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations

Abstract

This article has been corrected to add affiliation information and to amend the caption for Figure 6A and B.

Original languageEnglish (US)
Pages (from-to)1078
Number of pages1
JournalAnnals of Oncology
Volume29
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Erratum: The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [Ann Oncol, 28, 9, (2017) (2256-2263)] DOI: 10.1093/annonc/mdx305'. Together they form a unique fingerprint.

Cite this